Using 'amenable mortality' as indicator of healthcare effectiveness in international comparisons: Results of a validation study

Journal of Epidemiology and Community Health

Volumn 67, Issue 2, 2013, Pages 139-146

  Mackenbach, Johan P ^a   Hoffmann, Rasmus ^a   Khoshaba, Bernadette ^b   Plug, Iris ^a   Rey, Grégoire ^c   Westerling, Ragnar ^d   Pärna, Kersti ^e   Jougla, Eric ^c   Alfonso, José ^f   Looman, Caspar ^a   McKee, Martin ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c INSERM   (France)

^d UPPSALA UNIVERSITY   (Sweden)

^e UNIVERSITY OF TARTU   (Estonia)

^f HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DATA PROCESSING; HEALTH CARE; HEALTH RISK; MORTALITY; POISSON RATIO; REGRESSION; RISK ASSESSMENT;

ARTICLE; CAUSE OF DEATH; COMPARATIVE STUDY; EUROPE; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH SURVEY; HUMAN; MASS COMMUNICATION; MORTALITY; REGRESSION ANALYSIS; STANDARD; VALIDATION STUDY;

CAUSE OF DEATH; DELIVERY OF HEALTH CARE; DIFFUSION OF INNOVATION; EUROPE; HUMANS; MORTALITY; POPULATION SURVEILLANCE; QUALITY OF HEALTH CARE; REGRESSION ANALYSIS;

EUROPE;

EID: 84872169634     PISSN: 0143005X     EISSN: 14702738     Source Type: Journal    
DOI: 10.1136/jech-2012-201471     Document Type: Article

References (59)

1. Nolte E, McKee M, Wait S. Research on health, health system and service evaluation. Handbook of Health Research Methods: Investigation, Measurement and Analysis Bowling A, Ebrahim S, eds Buckingham: Open University Press, 2005 12-43.
2. Rutstein DD, Berenberg W, Chalmers TC, et al. Measuring the quality of medical care. A clinical method. New Engl J Med 1976;294:582-8.
3. Holland WW. The "avoidable death" guide to Europe. Health Policy 1986;6:115-17.
4. Holland W. Avoidable death as a measure of quality. Qual Assur Health Care 1990;2:227-33.
5. Charlton JR, Holland WW, Lakhani A, et al. Variations in avoidable mortality and variations in health care. Lancet 1987;1:858.
6. Charlton JR, Hartley RM, Silver R, et al. Geographical variation in mortality from conditions amenable to medical intervention in England and Wales. Lancet 1983;1:691-6.
7. Mackenbach JP, Bouvier-Colle MH, Jougla E. "Avoidable" mortality and health services: a review of aggregate data studies. J Epidemiol Community Health 1990;44:106-11.
8. Holland WW, ed. European Community Atlas of Avoidable Mortality. Oxford: Oxford University Press, 1988.
9. Holland WW, ed. European Community Atlas of Avoidable Death. 2nd edn. Oxford: Commission of the European Communities/Oxford University Press, 1991.
10. Jozan P, Prokhorskas R. Atlas Of Leading And 'Avoidable' Cause Of Death In Countries of Central and Eastern Europe. Budapest: Hungarian Central Statistical Office Publishing House, 1997.
11. Department of Health. The NHS Outcomes Framework 2012/13. London: Department of Health, 2010.
12. Commonwealth Fund. State Scorecard. 2011. http://wwwcommonwealthfundorg/Maps-and-Data/State-Data-Center/State-Scor ecardaspx (accessed 22 Dec 2011).
13. Desai M, Nolte E, Karanikolos M, et al. Measuring NHS performance 1990-2009 using amenable mortality: interpret with care. J R Soc Med 2011;104:370-9.
14. Andreev EM, Nolte E, Shkolnikov VM, et al. The evolving pattern of avoidable mortality in Russia. Int J Epidemiol. 2003;32:437-46.
15. Albert X, Bayo A, Alfonso JL, et al. The effectiveness of health systems in influencing avoidable mortality: a study in Valencia, Spain, 1975-90. J Epidemiol Community Health 1996;50:320-5.
16. Nolte E, McKee M. Variations in amenable mortalityetrends in 16 high-income nations. Health Policy 2011;103:47-52.
17. Nolte E, McKee M. Measuring the health of nations: analysis of mortality amenable to health care. BMJ 2003;327:1129.
18. Nolte E, Scholz R, Shkolnikov V, et al. The contribution of medical care to changing life expectancy in Germany and Poland. Soc Sci Med 2002;55:1905-21.
19. Logminiene Z, Nolte E, McKee M, et al. Avoidable mortality in Lithuania: 1991-199 compared with 1970-1990. Public Health 2004;118:201-10.
20. Nolte E, McKee CM. Measuring the health of nations: updating an earlier analysis. Health Affairs 2008;27:58-71.
21. Mackenbach JP. Health care expenditure and mortality from amenable conditions in the European Community. Health Policy 1991;19:245-55.
22. OECD. Health Care Systems: Efficiency And Policy Settings. Paris: OECD, 2010.
23. Mackenbach JP, Stronks K, Kunst AE. The contribution of medical care to inequalities in health: differences between socio-economic groups in decline of mortality from conditions amenable to medical intervention. Soc Sci Med 1989;29:369-76.
24. Kunitz SJ, McKee M, Nolte E. State political cultures and the mortality of African Americans and American Indians. Health Place 2010;16:558-66.
25. Baburin A, Lai T, Leinsalu M. Avoidable mortality in Estonia: exploring the differences in life expectancy between Estonians and non-Estonians in 2005-2007. Public Health. 2011;125:754-62.
26. Stirbu I, Kunst AE, Bopp M, et al. Educational inequalities in avoidable mortality in Europe. J Epidemiol Community Health 2010;64:913-20.
27. Stirbu I, Kunst AE, Bos V, et al. Differences in avoidable mortality between migrants and the native Dutch in The Netherlands. BMC Public Health 2006;6:78.
28. Nolte E, McKee M. Does Health Care Save Lives? Avoidable Mortality Revisited. London: Nuffield Trust, 2004.
29. Plug I, Hoffmann R, Mackenbach J. AMIEHS Avoidable Mortality in the European Union: Towards Better Indicators for the Effectiveness of Health Systems. Volume 1: Final Report. Rotterdam: Department of Public Health, Erasmus MC, 2011.
30. Rey G, Aouba A, Pavillon G, et al. Cause-specific mortality time series analysis: a general method to detect and correct for abrupt data production changes. Popul Health Metr 2011;9:52.
31. Black N, Murphy M, Lamping D, et al. Consensus development methods: a review of best practice in creating clinical guidelines. J Health Serv Res Policy 1999;4:236-48.
32. Lundgren JD, Phillips AN, Vella S, et al. Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:153-60.
33. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. New Engl J Med. 1987;317:185-91.
34. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-81.
35. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91.
36. Lin DY, Fischl MA, Schoenfeld DA. Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials. Stat Med 1993;12:835-42.
37. Phillips AN, Grabar S, Tassie JM, et al. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS 1999;13:2075-82.
38. Munoz A, Gange SJ, Jacobson LP. Distinguishing efficacy, individual effectiveness and population effectiveness of therapies. AIDS 2000;14:754-6.
39. Hamers FF, Downs AM. The changing face of the HIV epidemic in western Europe: what are the implications for public health policies? Lancet. 2004;364:83-94.
40. Devita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970;73:881-95.
41. Frei E 3rd, Gehan EA. Definition of cure for Hodgkin's disease. Cancer Res 1971;31:1828-33.
42. Reece DE, Phillips GL. Intensive therapy and autotransplantation in Hodgkin's disease. Stem Cells 1994;12:477-93.
43. Duffy SW, Tabar L, Olsen AH, et al. Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the breast screening programme in England. J Med Screen 2010;17:25-30.
44. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2011;(1):CD001877.
45. Autier P, Boniol M, Gavin A, et al. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ 2011;343:d4411.
46. McGuire WL. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 1978;5:428-33.
47. Hamilton M, Thompson EM, Wisniewski TK. The role of blood-pressure control in preventing complications of hypertension. Lancet 1964;1:235-8.
48. Stroke Unit Trialists' Collaboration. Collaborative systematic review of the randomised trials of organised inpatient (stroke unit) care after stroke. BMJ 1997;314:1151-9.
49. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New Engl J Med 1989;321:406-12.
50. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. New Engl J Med 1991;324:509-16.
51. Yudkin JS, Lipska KJ, Montori VM. The idolatry of the surrogate. BMJ 2011;343:d7995.
52. Britton A, McKee M, Black N, et al. Choosing between randomised and non-randomised studies: a systematic review. Health Technol Assess 1998;2:ieiv, 1-124.
53. Verdecchia A, Guzzinati S, Francisci S, et al. Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer 2009;45:1042-66.
54. Hamdy RC. Hypertension: a turning point in the history of medicine.and mankind. South Med J 2001;94:1045-7.
55. Anon. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J (Clin Res Ed) 1985;291:97-104.
56. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985;1:1349-54.
57. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.
58. Corrao G, Nicotra F, Parodi A, et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension 2011;58:566-72.
59. Barker WH, Mullooly JP, Linton KL. Trends in hypertension prevalence, treatment, and control: in a well-defined older population. Hypertension 1998;31:552-9.